Former CEO of California Stem Cell Agency Named to Board of Firm that Received $19 Million From the Agency
By David Jensen,
California Stem Cell Report
| 07. 07. 2014
Untitled Document
Alan Trounson, the former president of the $3 billion California stem cell agency, today was named to the board of a company that has
received $19.4 million from the agency, raising fresh and serious questions about conflicts of interest at the state-funded research program.
Announcement of the appointment came only seven days after Trounson left state employment. Trounson has been dogged for some time with questions about his relationship to the company,
StemCells, Inc., of Newark, Ca., and its co-founder, eminent
Stanford researcher
Irv Weissman, who sits on the company’s six-man board and is chairman of its scientific advisory board.
StemCells, Inc., announced Trounson’s appointment in
a press release this morning. The publicly traded firm said it was “thrilled” to have Trounson on its board. The first sentence of its press release noted that he had served as head of “the largest scientific funding body for stem cell research in the world.”
Weissman is director of the
Institute of Stem Cell Biology and Regenerative Medicine at Stanford. He has
received $34.7 million from the agency...
Related Articles
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...
By Adam Zewe, MIT News | 02.07.2024
A tiny device built by scientists at MIT and the Singapore-MIT Alliance for Research and Technology could be used to improve the safety and effectiveness of cell therapy treatments for patients suffering from spinal cord injuries.
In cell therapy, clinicians...